Patients with psoriasis who used biologic therapies had a lower risk for incident psoriatic arthritis than those who were biologic-naive.

Amgen’s phase 3 OASIZ 301 trial shows dazodalibep significantly improves systemic disease activity in adults with moderate to severe Sjögren disease at week 48.

Generalized pustular psoriasis is associated with elevated mortality and comorbidity risk compared with psoriasis vulgaris and controls.

Women who deliver preterm have lower vitamin D concentrations than women who deliver at term, according to recent study results.

Phase 3 EMBARQ-CSU1 and EMBARQ-CSU2 trials show barzolvolimab significantly improves UAS7 and complete response rates in antihistamine-refractory CSU.

Out of all of the hematological parameters examined, only neutrophil-to-monocyte ratio was associated with ocular involvement in rosacea.

Combining manual artifact detection with automated trough-to-peak amplitude scoring optimizes skin conductance measurement of thermal pain.

Significant imbalances in sex hormones and oxidative stress were seen among women with severe acne vulgaris when compared with healthy controls.

The FDA has updated labeling for Kybella (deoxycholic acid) to warn clinicians of persistent nodules, masses, and adverse events linked to off-label use.

The FDA has accepted an NDA with Priority Review for oral dersimelagon to treat erythropoietic protoporphyria and X-linked protoporphyria.

All participating US comprehensive cancer centers are experiencing a shortage of at least one anticancer agent.